> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Issues Lengthy 483 to Sun Pharmaceutical
- URL: https://www.fdaweb.com/fda-issues-lengthy-483-to-sun-pharmaceutical/
- Published: 2016-12-07T12:00:00.000Z
- Updated: 2026-09-14T21:53:01.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137513

An FDA inspection at the Sun Pharmaceutical facility in Halol, India, resulted in a 14-page FDA-483 list of observations, Bloomberg News [reports](https://www.bloomberg.com/news/articles/2016-12-07/sun-pharma-halol-plant-inspection-resulted-in-14-page-fda-report?ref=fdaweb.com). A Mumbai securities analyst told the news service that the length of the report gives it a negative connotation. “We don’t know if it will be all negative,” he said, “but what it simply means is there are many portions you will need to talk about, that’s why you would need so much space.”

FDA issued a Warning Letter to the Halol facility in 2015\. The news story says the latest agency inspection came after Sun invited it back to review a year’s worth of remediation efforts in hopes that the Warning Letter would be lifted and new products could once again be launched for the U.S. market.